Private Capital Advisors Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.1% during ...

Eli Lilly and Company (NYSE ... Its flagship products include Humalog, Trulicity, Alimta, and Taltz. The company has also emerged as a leader in the growing obesity treatment market, with its ...

RFG Advisory LLC boosted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 13.4% in the fourth quarter, ...

Eli Lilly and Company discovers ... Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Billionaire investor Ray Dalio says dollar bulls should worry about crypto.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

and Trulicity ($1.3 billion for Type 2 diabetes). The company's non-incretin revenue increased by 17% overall, thanks to its oncology, immunology, and neuroscience portfolios. Recently, Eli Lilly ...